

56 **Keywords:** SARS-CoV-2, vaccination, adverse events, thrombosis/thrombocytopenia syndrome,
57 Bayesian networks, model

58

59

60 **Author contributions:**

61 Conception and design: JL, AB, KRS, CLL, HJM, KM

62 Acquisition of data: JL, AB, KRS, CLL, HJM, JES, SJB, AKE

63 Analysis and interpretation: CLL, HJM, KM, JL, JES, SJB, MW

64 Drafting the article: CLL

65 Revising article for important intellectual content: All authors

66 Final approval of submitted version: All authors

67

68

69 **HIGHLIGHTS**

- 70 • AZ vaccination risk-benefit analysis must consider age/community transmission level
- 71 • AZ vaccine benefits far outweigh risks in older age groups and during high transmission
- 72 • AZ vaccine-associated TTS lower fatality than COVID-related atypical blood clots
- 73 • Bayesian networks utility for risk-benefit analysis of rapidly evolving situations
- 74 • BNs allow integrating multiple data sources when large datasets are not available

75

76

77

78

79

80

81

82

83 1. INTRODUCTION

84

85 The AstraZeneca ChAdOx1 (AZD1222) COVID-19 vaccine (AZ vaccine) has been widely used
86 globally, with one billion doses released in over 170 countries by August 2021 [1]. The vaccine is
87 highly effective against symptomatic infection, serious illness and death from COVID-19 [2-4]. In
88 March 2021, reports of AZ vaccine-associated Thrombosis with Thrombocytopenia Syndrome (TTS)
89 began emerging from multiple countries, including Norway [5], Canada [6], the U.K. [7], and Australia
90 [8], and appeared to be more common in younger age groups [8]. Although the incidence of TTS was
91 very low (<3/100,000 first doses in any age group in Australia), initial reports of high case fatality rates
92 (CFR) (44% in Germany [9] and 18% in United Kingdom [7]) prompted some countries to recommend
93 alternative COVID-19 vaccines in younger persons.

94 In Australia, a change in recommendation was made in April 2021 to preference the Pfizer/BioNTech
95 (BNT162b2) COVID-19 vaccine over the AZ vaccine in those aged <50 years [10]. In June 2021, after
96 the death of a 52-year-old woman, the recommendation was revised to preference the Pfizer vaccine
97 over the AZ vaccine in those aged <60 years [11, 12]. The AZ vaccine-associated TTS cases and deaths
98 received significant media attention in Australia, resulting in increased vaccine reluctance, and
99 uncertainty amongst the public and clinicians about risks versus benefits of vaccination [13]. The only
100 other COVID-19 vaccine available in Australia at the time (and up to early September 2021) was the
101 Pfizer vaccine, but limited supplies meant that those choosing the Pfizer vaccine had to wait weeks or
102 months to be vaccinated.

103 Initial risk assessments and decisions about age-based recommendations for the AZ vaccine in Australia
104 were made at a time when there was almost no local community transmission of COVID-19.
105 Unfortunately, since late June 2021, outbreaks have occurred in multiple states and territories, resulting
106 in prolonged lockdowns of millions of people in New South Wales (NSW), Victoria (VIC), and the
107 Australian Capital Territory (ACT) [14]. Therefore, the risks versus benefits of the AZ vaccine changed
108 dramatically over a few weeks, and those aged <60 years have been advised to see a doctor to help them
109 make an individual risk assessment.

110 On 29 June 2021, the Australian Government produced a document on ‘Weighing up the potential
111 benefits against the risk of harm from COVID-19 Vaccine AstraZeneca’ for clinicians to help patients
112 make informed decisions [15]. The document provides helpful information for each age group such as
113 the risk of TTS versus the number of deaths, intensive care unit (ICU) admissions, and hospitalisations
114 prevented by vaccination under low, medium, and high levels of transmission. However, calculations
115 of risks versus benefits changed rapidly because of many factors, including evolving incidence and CFR
116 of TTS (both in Australia and internationally), changing levels of community transmission, changing
117 age distribution of cases associated with the arrival of the delta variant (the predominant variant in
118 Australia since June 2021), and new data on vaccine effectiveness against the delta variant. These and
119 other factors that influence risk-benefit analysis are likely to continue to evolve at a rapid pace.

120 To address the challenge of providing up-to-date risk-benefit analysis of COVID-19 vaccination, one
121 of the authors (JL) suggested to the Immunisation Coalition
122 (<https://www.immunisationcoalition.org.au/>) that they support the development of the COVID-19 Risk
123 Calculator (CoRiCal), a set of tools designed to facilitate shared decision making between clinicians
124 and patients. The Immunisation Coalition is a not-for-profit organization with representation from
125 clinical and other professional groups interested in promoting vaccination best practice in Australia.
126 CoRiCal aims to support informed risk assessment by providing relevant and accurate estimates of the
127 risks and benefits of COVID-19 vaccines, taking into account locally relevant factors.

128 This paper describes the first CoRiCal model, focused on risk-benefit analysis of the AZ vaccine. The
129 model was developed using a Bayesian network (BN), which allows the model’s inputs to be updated
130 easily as the outbreak situation changes and as scientific evidence evolves. The model aims to provide
131 more precise risk-benefit analysis of AZ vaccination by comparing the risk of death from vaccine-
132 associated TTS versus the risk death from i) COVID-19 infection, and ii) atypical severe blood clots
133 (cerebral venous sinus thrombosis [CVST] and portal vein thrombosis [PVT]) related to COVID-19
134 infection. The model enables scenario analysis based on age, sex, current transmission intensity,
135 predominant SARS-CoV-2 variant, number of AZ vaccine doses received, and vaccine effectiveness
136 against symptomatic infection and death. The model could also be extended for outcomes other than

137 death (e.g., ICU admission, long COVID), other vaccines, other adverse events following immunization
138 (AEFI), or adapted for use in other countries.

139

140 2. METHODS

141 2.1. Bayesian networks

142 BNs are acyclic graphical models that explicitly represent relationships between variables in terms of
143 conditional probabilities [16]. Variables are represented by nodes, each categorized into several possible
144 states (e.g., yes/no, high/low, age groups). Links (or edges) represent the relationships between nodes
145 and point in the direction from a parent node (independent variable) to a child node (dependent variable)
146 (Figure 1). Nodes are quantified using probability tables that define the probability of a node being in a
147 given state, either based on some prior distribution (for nodes with no parent nodes) or conditional on
148 the states of all parent nodes i.e., conditional probability tables (CPTs).

149 BN modelling frameworks offer many advantages relevant to the problem at hand. Firstly, BNs provide
150 visual and transparent representation of relationships between variables and the probabilistic
151 assumptions between each variable. The graphical structure enables users to understand how the system
152 has been modelled, clearly shows the underlying assumptions, how model outputs were derived, and
153 enables interactive scenario analysis. Secondly, CPTs can be derived from a range of data formats,
154 allowing relevant data to be integrated from diverse sources including studies, reports, and expert
155 opinion. Thirdly, the probabilistic framework of BNs is well suited to risk analysis where the uncertainty
156 surrounding estimates can be tested through sensitivity analysis for a range of plausible inputs. Finally,
157 model assumptions and CPTs can be updated easily as more information become available or as the
158 situation evolves. Rapid adaptability is particularly important for modelling rapidly evolving situations
159 such as outbreaks.

160 BNs have been used for a variety of COVID-19 models, including modelling transmission and outbreak
161 response [17, 18], decision making [19], risk analysis [20, 21], risk assessment and contact tracing [22,

162 23], interpretation of SARs-CoV-2 test results [24], and predictive diagnosis [25]. However, to our
163 knowledge, BNs have not yet been applied for risk-benefit analysis of COVID-19 vaccines.

164

165 **2.2. Model design**

166 Our BN model structure was based on the best available scientific evidence from multiple sources.
167 Evidence was integrated using facilitated expert elicitation, with subject matter experts (JL, AB, KRS,
168 AKE, CLL, Thrombosis & Haemostasis Society of Australia and New Zealand [THANZ]) working
169 closely with experienced BN modellers (HJM, KM, CLL). The four subject matter experts included
170 clinicians and researchers with expertise in infectious disease epidemiology, virology, thrombosis,
171 general practice, and public health. The experts defined the scope of the model, key outcome variables
172 of interest, and major predictor variables (inputs) that influenced the outcomes. Experts reviewed
173 published literature and reports to determine whether there was sufficient evidence to include each
174 predictor variable in the model. Predictors were linked to outcomes if there were sufficient evidence
175 and data to quantify the conditional probabilities between them.

176 Based on the discussions between the experts and modellers, and evidence collected by the experts, a
177 draft BN model structure was derived by the modellers, then reviewed and refined with the team over
178 several iterations of facilitated discussions. To parameterize the model, questionnaires were developed
179 to help experts structure the systematically collected data into CPTs. Variables were not linked if there
180 were only weak quantitative relationships between them because the links would have little impact on
181 model predictions. Data were updated as new evidence became available during the model development
182 process from July-September 2021. External consistency was considered during model design so that
183 predictions were consistent with other commonly used information sources such as the Australian
184 Technical Advisory Group on Immunisation (ATAGI) and the Therapeutic Goods Administration
185 (TGA), e.g., using the same age groups and definitions of low/medium/high community transmission
186 intensity (equivalent to 0.05%/0.45%/5.76% of population infected over 6 months) [15].

187

188 **2.3. Atypical severe blood clots**

189 TTS is a rare and atypical form of blood clotting associated paradoxical thrombosis and low platelets.
190 TTS is immunologically mediated, and can be triggered by medications (e.g., heparin) or vaccines (e.g.,
191 AZ vaccine) [26]. TTS is diagnosed on the basis of clinical criteria and includes atypical severe blood
192 clots such as CVST and splanchnic vein thrombosis (SVT) [27, 28], which have also been reported in
193 COVID-19 patients [29, 30]. CVST and SVT are distinct from the common types of venous
194 thromboembolism such as deep vein thrombosis or pulmonary embolus, or other types of
195 thrombocytopenia and have the highest risk of mortality in this group. SVT includes portal vein
196 thrombosis (PVT), Budd Chiari Syndrome and mesenteric vein thrombosis. The data included in the
197 model focused on PVT as it is the most common type of SVT, and has been specifically reported post-
198 COVID, enabling a direct comparison. Our model therefore focused on comparing the risk of AZ
199 vaccine-associated TTS with the risk of CVST and PVT in COVID-19 patients.

200

201 **2.4. Data sources**

202 While the assumptions and model structure are defined by experts, the CPTs were based on empirical
203 data. Experts compiled evidence from peer-reviewed literature, government websites and reports, and
204 through discussion with external clinical experts (e.g., haematologists regarding the evidence for AZ
205 vaccine- associated TTS, and background rates of CVST and PVT). Official data from Australian
206 authorities were used wherever possible (e.g., local data on AZ vaccine-associated TTS). Otherwise,
207 data were obtained from other robust and publicly available sources (e.g., background rates of CVST
208 and PVT). Data from different sources were harmonised for the CPTs, e.g., summarising data to match
209 the age groups used in the BN. Data analyses were conducted for some variables to convert them into
210 probabilities for the CPTs, e.g., converting incidence of COVID-19 into probability of infection over 6
211 months for the *Intensity of local transmission* node. Table 1 [31-40] and Appendix A provide a summary
212 of data sources, model assumptions, and rationale.

213 The model includes default prior distributions for age group (using age distribution of Australia), gender
214 (50% male, 50% female), SARS CoV-2 variants (90% delta, 10% alpha/ancestral virus), and vaccine
215 coverage (70% of population received first dose, 35% received two doses). The prior distributions do
216 not affect the results of scenario analyses, e.g., if delta was selected in the variants node, the model
217 outputs relate to delta only regardless of the prior distribution of variants entered into the model. Prior
218 distributions can be changed to model other scenarios, e.g., different distributions of variants, and
219 different levels of vaccine coverage.

220

221 **2.5. Model validation**

222 The final model was assessed by subject matter experts and the modelling team together, to determine
223 if the structure, variables, and assumptions reflected current knowledge and evidence. The model's
224 predictive ability was not validated against a dataset because model parameters were not learned from
225 data. Rather, we validated each section of the model by defining a range of scenarios and manually
226 assessed whether model outputs were consistent with our assumptions. Manual quantitative validations
227 were conducted by a subject matter expert/BN modeller (CLL), a mathematician/statistician/BN
228 modeller (KM) and a biostatistician (MW). Scenarios used for manual validations are provided in
229 Appendix B. All authors evaluated the biological plausibility of estimates, e.g., for COVID-19 patients,
230 the probability of dying from COVID-19 related atypical blood clots should be lower than the total
231 probability of dying from COVID-19.

232

233 **2.6. Sensitivity analysis**

234 To determine how often model assumptions need to be updated, sensitivity analysis was conducted for
235 three predictor variables that were considered most likely to change over time. We examined actual
236 changes in the reported incidence of AZ vaccine-associated TTS cases and deaths in Australia in
237 August-September 2021. We also examined i) plausible differences in age-specific CFR for COVID-

238 19 in Australia (e.g., if higher CFR with new variants or because of an overwhelmed health system, and
239 ii) plausible reductions in vaccine effectiveness against symptomatic COVID-19 infection and death.

240 ***Incidence and CFR of vaccine-associated TTS:*** From July-September 2021, reported incidence of AZ
241 vaccine-associated TTS and related deaths in Australia fluctuated by week because of low numbers.
242 We examined ATAGI reports from 25/8/2021, 1/9/2021, 8/9/2021, and 15/9/2021 [36-39] to determine
243 how fluctuations in data affected our model predictions of age-specific TTS-related deaths over these
244 weeks.

245 ***Age-specific CFR for COVID-19 in Australia:*** By 31/8/2021, COVID-19 CFR in Australia were very
246 low for younger age groups, with less than five deaths during the entire pandemic in each male/female
247 subgroups in those aged 0-9, 10-19, 20-29, 30-39, and 40-49 years. We examined changes in CFR if
248 (theoretically) there was one extra death or five extra deaths in each age-sex subgroup, and the potential
249 impact of these changes on model predictions on COVID-19 related deaths.

250 ***Vaccine effectiveness against symptomatic infection and death:*** We examined the sensitivity of model
251 outputs to reduced vaccine effectiveness against the delta variant using theoretical assumptions of 5%
252 and 10% reduction in effectiveness against both symptomatic infection and death.

253

254 3. RESULTS

255 3.1. Model description

256 The final BN structure (Figure 2) synthesises the assumptions regarding probabilistic relationships
257 between variables and outcomes. Table 2 provides a summary of all nodes (n1 to n20) and their
258 parent/child relationships. The model was designed to predict five outcomes:

- 259 i. Probability of dying from AZ vaccine-associated TTS (n6) – depending on age (n2), 1st or 2nd
260 dose of AZ vaccine (n1);
- 261 ii. Background probability of deaths from CVST and PVT (in those who have not had AZ vaccine
262 or COVID-19 infection) (n7, n8). Estimates were converted to probability of events over 6

- 263 weeks to enable comparison with the probability of vaccine-associated TTS, which generally
264 occurs within 6 weeks of vaccination;
- 265 iii. Probability of symptomatic COVID-19 infection – depending on age (n2), sex (n5), variant
266 (n3), intensity of community transmission (n4), vaccine effectiveness against symptomatic
267 infection (n9);
- 268 iv. Probability of dying from COVID-19 (n18) – depending on age (n2), sex (n5), variant (n3),
269 intensity of community transmission (n4), vaccine effectiveness against symptomatic infection
270 (n9), vaccine effectiveness against death (n10); and
- 271 v. Probability of CVST and PVT deaths (n19, n20) related to COVID-19 infection – depending
272 on sex (n5).

273

274 The BN includes five input nodes (orange) that could be used for scenario analysis based on AZ vaccine
275 doses (n1), age (n2), sex (n5), variant (n3) and intensity of community transmission (n4). Community
276 transmission scenarios were converted to probability of infection over six months to more readily
277 compare the risks versus benefits of vaccination, which is expected to be effective for at least six
278 months. Scenarios were selected based on ATAGI definitions of low/medium/high risk [15], other
279 scenarios that users could relate to (e.g., 1000 cases/day in NSW), and general scenarios that could be
280 adapted to any setting (e.g., 1% chance of infection over 6 months). The model includes nine
281 intermediate nodes (yellow) where modellers can readily update evidence on incidence of TTS (n6),
282 background incidence of CVST and PVT (n7, n8), relative risk of infection based on age and variant
283 (n11), vaccine effectiveness (n9, n10), and incidence and CFR of COVID-19 related CVST and PVT
284 (n12, n13).

285 Two versions of the model were built using different definitions of the ‘AZ vaccine doses (n1)’ node:

- 286 • Version 1: AZ vaccine doses defined as no doses, 1st dose, and 2nd dose. This version was used
287 to estimate the probability of vaccine-associated TTS with each dose of vaccine.

- 288 • Version 2: AZ vaccine doses defined as no doses, received only one dose, and received both
289 doses. This version was used to estimate the probability of deaths in the population based on
290 vaccine coverage rates.

291

292 **3.2. Model validation**

293

294 A model walk-through indicated that subject matter experts agreed the model structure matched their
295 understanding of the problem space in terms of the relevant predictors and relationships drawn from the
296 external data sources. Independent manual calculations by three authors (CLL, MW, KM) of
297 probabilities of selected outcomes were consistent with model predictions (Appendix B).

298 A minor anomaly was detected in the model through assessment of biological plausibility. For COVID-
299 19 cases in younger age groups (females <30 years and males <10 years), the estimated probability of
300 dying from COVID-19 was lower than the probability of dying from COVID-19 related atypical severe
301 blood clots. The reason for this anomaly is that data for COVID-19 CFR in Australia were used for the
302 CPTs, and there have been no deaths to date in these age-sex subgroups (Table A3), while data on
303 COVID-19 related atypical blood clots were extracted from a study where data were predominantly
304 sourced from the USA and Europe, where high CFRs could have resulted from an overwhelmed health
305 system during the outbreak. Although the discrepancies in probabilities were extremely low (probability
306 of dying from COVID-19 related atypical blood clots <0.0002% higher than dying from COVID-19
307 itself), the anomaly highlights that the model predictions should be used as broad estimates rather than
308 exact risks.

309

310 **3.3. Comparison of estimated deaths prevented from COVID-19 under different scenarios of** 311 **community transmission intensity and vaccine coverage, with estimated cases and deaths** 312 **from AZ vaccine-associated TTS.**

313

314 Model version 2 was used to estimate COVID-19 deaths prevented over 6 months per million population
315 if 70% had a first dose, and 35% had two doses. Figures 3a, 3b, and 3c show the estimated deaths
316 prevented for each age group under different levels of community transmission:

- 317 • Low transmission (Figure 3a), similar to 1st wave in Australia in 2020, equivalent to 0.05% of
318 population infected over 6 months;
- 319 • Medium transmission (Figure 3b), similar to 2nd wave in VIC in 2020, equivalent to 0.45% of
320 population infected over 6 months; and
- 321 • High transmission (Figure 3c), similar to Europe in January 2021, equivalent to 5.76% of
322 population infected over 6 months.

323

324 The model shows that for a million people aged ≥ 70 years where 70% have had first dose and 35% two
325 doses, an estimated 25 deaths would be prevented under low transmission (Fig 3a) versus >3000 deaths
326 prevented under high transmission (Fig 3c), with <1 expected death from TTS (Fig 3d). In a million
327 people aged 60-69 years with the same vaccine coverage, the model estimates two deaths prevented
328 under low transmission, and 260 deaths prevented under high transmission, with <1 expected death
329 from TTS. In contrast, for a million 20-29 year-olds with the same vaccine coverage, <0.1 deaths would
330 be prevented under low transmission, ~9 deaths prevented under high transmission, with <1 expected
331 death from TTS. Details on calculations are provided in Appendix C.

332

333 **3.4. Comparison of risk of AZ vaccine-associated TTS with risk of atypical blood clots (CVST** 334 **and PVT) in COVID-19 infected patients**

335

336 Up to 25/8/2021 in Australia, age-specific incidence of AZ vaccine-associated TTS cases ranged from
337 16 to 27 per million first doses (Table 1), with an overall CFR of ~5% (6 deaths out of 115 cases).
338 Based on annual background rates of CVST and PVT reported by Kristoffersen *et al.* [27] and Ageno
339 *et al.* [28], our model estimated 6-week incidence of 0.38 (age <20 years) to 2.69 (age ≥ 70 years) cases
340 per million, and overall CFR ranging from 7.0% to 21.6% from youngest to oldest age groups (Table

341 A7). The background CFR for CVST and PVT (combined) range from 0.03 (age <20 years) to 0.58
342 (age ≥70 years) per million over 6 weeks, compared to CFR of 0.83 to 1.40 per million first doses of
343 AZ vaccine depending on age (Table 3).

344

345 Model assumptions on the incidence and CFR of CVST and PVT in COVID-19 patients were obtained
346 from a retrospective cohort study using linked electronic health records predominantly from the USA
347 and Europe [30] because there were insufficient data from Australia. Model version 1 estimated that
348 overall fatality from atypical severe blood clots (CVST and PVT combined) in COVID-19 patients were
349 51.1 and 37.3 per 100,000 in males and females, respectively. Figure 4 shows that the probability of
350 developing atypical blood clots in COVID-19 patients was 14-28 times more likely than developing
351 TTS after the first dose of the AZ vaccine, depending on age group and sex (Figure 4, dashed lines).
352 The probability of dying from COVID-19 infection-related atypical blood clots in COVID-19 patients
353 was 58-126 times more likely than dying from TTS after the first dose of AZ vaccine, again depending
354 on age group and sex (Figure 4, solid lines).

355

356 **3.5. Sensitivity analysis**

357

358 *Incidence and CFR of AZ vaccine-associated TTS*

359 ATAGI reports from 25/8/2021 to 15/9/2021 [36-39] showed minor changes in the incidence of
360 vaccine-associated TTS in Australia, and CFR ranging from 5.2% to 6.4% (Table 3). The model outputs
361 showed that estimated deaths from TTS per million first doses did not change significantly over this
362 time period, and ranged from differences of -0.08 to 0.37 deaths per million (depending on age group)
363 when comparing data from 25/8/2021 with subsequent reports. Therefore, minor fluctuations in CFR
364 from TTS did not have any significant influence on the point estimates of the number deaths at a
365 population level. Because of the small number of TTS cases and deaths in Australia so far, the 95%
366 confidence intervals (CI) for CFR were wide, ranging from 1.9% to 12.2% over the four reports (Table
367 3). Our model currently assumes a CFR of 5%; it is plausible that true CFR is twice as high (10%), and
368 if so, model estimates of TTS related deaths would be doubled.

369

370 *Age-specific CFR for COVID-19 in Australia*

371 By August 2021, CFR for COVID-19 in Australia was 1.84% in males and 1.94% in females. In those
372 aged under 50 years, CFR was <0.1% in both sexes (Appendix A). If there was one extra death in each
373 age-sex subgroup during this time, CFR would have increased the most in 60-69 year-olds and the least
374 in 20-29 year-olds, but by less than 0.06% in any subgroup (Figure 5). The model was most sensitive
375 to changes in the 60-69 year-old age group because of the small case numbers (small denominator). If
376 there were five extra deaths in each age-sex subgroup, CFR would have increased by less than 0.3% in
377 any subgroup. Therefore, our model was not very sensitive to minor changes in number of reported
378 deaths, and model estimates of deaths per million would have differed by less than 0.06% or 0.3% if
379 there were one or five extra deaths in any age-sex subgroup, respectively.

380

381 *Vaccine effectiveness against symptomatic infection and death*

382 Our model shows that for a population where 70% has received first dose and 35% has received two
383 doses, a theoretical 5% or 10% reduction in vaccine effectiveness against the delta variant results in a
384 7.1% or 15.1% increase in estimated deaths, respectively (Table 4). Therefore, sensitivity analyses
385 show that model predictions of deaths are much more sensitive to changes in vaccine effectiveness than
386 to changes in incidence and CFR of TTS, or changes in CFR from COVID-19 infection.

387

388

389 **4. DISCUSSION**

390

391 Our model demonstrates that risk-benefit analysis of the AZ vaccine is complex, and depends on
392 multiple factors including age, sex, vaccine effectiveness, and locally specific factors such as the
393 intensity of community transmission, local incidence and CFR of TTS, and CFR from COVID-19. The
394 model outputs and scenario analysis could facilitate more informed decision making between clinicians
395 and individuals, e.g., by considering age, sex, community transmission, and local data on TTS. The
396 model could also provide decision support at a public health level; if the priors were set to represent the

397 population in age and sex distribution, vaccination coverage, circulating variants and level of
398 community transmission, the model outputs could be used to estimate deaths or deaths prevented. To
399 our knowledge, this is the first example of the use of Bayesian networks for risk-benefit analysis for a
400 COVID-19 vaccine.

401

402 Our model quantifies the risks (deaths from TTS) versus benefits from vaccination (deaths prevented)
403 for different age groups under different levels of community transmission (Figure 3). While the benefits
404 are significantly greater during higher transmission (especially for older age groups), decisions about
405 vaccination should be based not only on the current level of transmission, but also potential future
406 scenarios. For example, higher transmission will be almost inevitable with lifting of public health
407 restrictions and opening of borders. We presented results for scenarios where 70% of the population
408 have had first dose and 35% have had two doses. Other vaccination coverage scenarios can be easily
409 defined in the model priors to assess the current vaccination coverage rates, or future vaccination targets.

410

411 To date, the CFR of TTS in Australia has been lower than those reported in other countries [7, 9].
412 Although numbers have been small, CFR have remained relatively stable throughout August-September
413 2021 (Table 3). Possible reasons for the lower CFR in Australia include early shift to Pfizer as the
414 preferred vaccine for those aged <60 years; detailed expert review of each case of serious and fatal
415 AEFI (reducing classification error) by state-based committees, ATAGI and TGA; high clinical
416 vigilance of TTS based on lessons learnt from earlier reports from other countries; and clinical
417 guidelines for vaccine providers on early diagnosis and referral of possible TTS cases [41-43]. Our
418 sensitivity analysis showed that fluctuations in observed CFR from TTS had only minor impact on
419 model outputs. Model assumptions can be readily updated if CFR changes significantly in the future.
420 While vaccine-associated TTS of any type can be serious and rarely fatal, mortality for those presenting
421 with atypical severe blood clots (CVST and PVT) in COVID-19 patients are estimated to be 58-126
422 times more likely than after the first dose of the AZ vaccine (Figure 4).

423

424 Sensitivity analyses showed that the estimates of COVID-19 related deaths were very sensitive to
425 changes in vaccine effectiveness. Therefore, model assumptions need to be updated to reflect evolving
426 evidence on vaccine effectiveness against current and future variants of the virus, waning immunity
427 over time, and effectiveness of vaccine boosters. From a public health perspective, our findings suggest
428 that a decrease in vaccine effectiveness will likely have important implications on disease burden. In
429 contrast, model outputs were not very sensitive to changes in age-specific CFR for COVID-19, and
430 updates to model assumptions are unlikely to be required unless changes are dramatic.

431

432 We used an innovative and flexible modelling framework which allows model assumptions to be easily
433 changed, either to reflect new data (e.g., vaccine effectiveness), to the evolving situation (e.g., intensity
434 of community transmission, changing CFR from TTS and COVID-19). While the current model is
435 designed to estimate deaths from vaccine versus disease, it could be readily adapted for other outcomes
436 (e.g., ICU admission, long COVID), other adverse events (e.g., immune thrombocytopenia), risk-
437 benefit assessment of other vaccines (e.g., myocarditis/pericarditis from mRNA vaccines), and other
438 types of scenario analysis (e.g., different combinations of vaccine doses and boosters). Our modelling
439 approach also enables the use of multiple sources of data. We have used Australian data wherever
440 possible and international sources if needed (e.g., low number of COVID-19 cases and vaccinations in
441 Australia means that international data on vaccine effectiveness were likely to be more accurate). Our
442 modelling approach therefore provides the potential for countries to develop a locally relevant risk-
443 benefit assessment tool for COVID-19 vaccination even if there are limited local data.

444

445 Another advantage of BNs is the visual and interactive interface that allows intuitive scenario analysis
446 for users and decision makers. This paper presents results of specific scenarios from our model, but we
447 aim to produce interactive versions of the model and make them freely available on the Immunisation
448 Coalition website (<https://www.immunisationcoalition.org.au/>). Interactive risk assessment tools for
449 COVID-19 have been developed for estimating the risk of hospitalization and death (e.g., QCOVID
450 tool in United Kingdom [44], COVID-19 risk tools in USA [45] and France [46], predicting clinical
451 outcomes [47], and assessing risk of infection from different activities [48-50]. Some tools were based

452 on analysis of millions (e.g., QCOVID [44]) or hundreds of thousands (e.g., ISARIC4C [47]) of medical
453 records. Our modelling approach provides an alternative option of developing risk assessment tools if
454 large datasets are not available, and model inputs need to be sourced from alternative sources. We have
455 not identified any web-based interactive tools that use Bayesian networks for risk-benefit analysis of
456 COVID-19 vaccines for use in clinical or public health settings.

457

458 Our results should be interpreted considering the model's limitations. There are uncertainties associated
459 with some of our model inputs, either because of limited data, or the use of data from other countries.

460 As illustrated with the anomaly regarding the risk of dying in younger persons, model outputs should
461 be considered as broad estimates rather than exact risks, but estimates can be improved over time as
462 more data become available. Our model provides population level estimates and does not consider
463 individual risks such as behaviour and comorbidities. We plan to develop future models that include
464 the individual's comorbidities, similar to the QCOVID tool [44] but specific for the Australian context.

465 In the results provided, we have assumed that 100% of infections were from the delta variant.

466 Assumptions of age distribution of delta cases (if unvaccinated) were obtained from data during the

467 early stages of the delta outbreak in NSW from June 2021. While vaccination rates were relatively low

468 then, older ages had higher vaccine coverage so infection rates for delta may have been underestimated

469 in these groups. Data on CVST and PVT were obtained from studies outside Australia and may not

470 reflect the local experience. The current model focuses on fatalities from COVID-19, TTS, and atypical

471 blood clots, but does not consider other risks (e.g., adverse events) or other benefits (e.g., cases of severe

472 COVID prevented, or broader societal benefits). Our model was not parameterised from any specific

473 datasets, so model outputs could not be directly validated by data. Nevertheless, the model provides a

474 powerful mechanism for complex synthesis of multiple sources of data, and the outputs reflect the latest

475 available knowledge.

476

477 In conclusion, we developed a novel approach to risk-benefit analysis for the AZ vaccine by using an

478 adaptable BN modelling framework. Our model enables more precise risk analysis based on

479 demographics, the outbreak situation, local data on vaccine-associated TTS, and the best available

480 international evidence on vaccine effectiveness and atypical blood clots. Although use of the AZ
481 vaccine is expected to gradually decrease in Australia over coming months, the model can be readily
482 adapted for use in other countries or risk-benefit assessment of other vaccines.

483

484 **Acknowledgements**

485 We thank Kim Sampson from Immunisation Coalition for facilitating the collaboration between
486 authors, and A/Prof Hassan Valley (La Trobe University, Melbourne, Australia) for contributions to
487 discussions about risk communication and data visualisation. We thank Aapeli Vuorinen (Columbia
488 University) for building the interactive risk assessment tool. Our Bayesian network model was built
489 using GeNIe Modeler (BayesFusion 2019), available free of charge for academic research and teaching
490 use from <https://www.bayesfusion.com/>. We thank the THANZ Vaccine-induced Immune Thrombotic
491 Thrombocytopenia (VITT) advisory group (in particular A/Prof Vivien Chen, Prof Huyen Tran, A/Prof
492 Jennifer Curnow, Dr Ibrahim Tohidi and Dr Danny Hsu) for their feedback about TTS related data.

493

494 **Funding**

495 This research did not receive any specific grant from funding agencies in the public, commercial, or
496 not-for-profit sectors. CLL was supported by an Australian National Health and Medical Research
497 Council (NHMRC) Fellowship (APP1193826).

498

499 **Conflicts of Interest**

500 The authors declare that they have no known competing financial interests or personal relationships that
501 could have appeared to influence the work reported in this paper.

502

503

504 **References**

- 505 1. University of Oxford *Oxford vaccine reaches one billion doses released*. 2021.
506 <https://www.ox.ac.uk/news/2021-07-29-oxford-vaccine-reaches-one-billion-doses-released>.

- 507 2. Merryn Voysey, et al., *Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)*
508 *against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South*
509 *Africa, and the UK*. The Lancet, 2021. **397**(10269): p. 99-111.
- 510 3. Merryn Voysey, et al., *Single-dose administration and the influence of the timing of the*
511 *booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a*
512 *pooled analysis of four randomised trials*. The Lancet, 2021. **397**(10277): p. 881-891.
- 513 4. Aziz Sheikh, et al., *SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital*
514 *admission, and vaccine effectiveness*. The Lancet, 2021. **397**(10293): p. 2461-2462.
- 515 5. Norwegian Institute of Public Health *Norwegian Institute of Public Health's recommendation*
516 *about AstraZeneca vaccine*. 2021. [https://www.fhi.no/en/news/2021/astrazeneca-vaccine-](https://www.fhi.no/en/news/2021/astrazeneca-vaccine-removed-from-coronavirus-immunisation-programme-in-norw/)
517 [removed-from-coronavirus-immunisation-programme-in-norw/](https://www.fhi.no/en/news/2021/astrazeneca-vaccine-removed-from-coronavirus-immunisation-programme-in-norw/).
- 518 6. Michael Franklin; Timm Bruch *Alberta doctors find 2nd case of blood clot linked to*
519 *AstraZeneca vaccine in Canada*. 2021. [https://calgary.ctvnews.ca/alberta-doctors-find-2nd-](https://calgary.ctvnews.ca/alberta-doctors-find-2nd-case-of-blood-clot-linked-to-astrazeneca-vaccine-in-canada-1.5391531)
520 [case-of-blood-clot-linked-to-astrazeneca-vaccine-in-canada-1.5391531](https://calgary.ctvnews.ca/alberta-doctors-find-2nd-case-of-blood-clot-linked-to-astrazeneca-vaccine-in-canada-1.5391531).
- 521 7. Medicines & Healthcare products Regulatory Agency, *Coronavirus vaccine - weekly*
522 *summary of Yellow Card reporting*. 2021, GOV.UK: United Kingdom.
523 [https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-](https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting)
524 [reactions/coronavirus-vaccine-summary-of-yellow-card-reporting](https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting).
- 525 8. Australian Government Department of Health, *COVID-19 vaccine weekly safety report - 12-*
526 *08-2021*, in *COVID-19 vaccine weekly safety report*. 2021: Australia.
527 <https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-12-08-2021>.
- 528 9. A. Greinacher, et al., *Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination*. N
529 Engl J Med, 2021. **384**(22): p. 2092-2101.
- 530 10. Australian Government Department of Health *Joint statement from ATAGI and THANZ on*
531 *Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine*
532 *AstraZeneca*. 2021. [https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-](https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca)
533 [thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-](https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca)
534 [astrazeneca](https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca).

- 535 11. Australian Government Department of Health *ATAGI statement on revised recommendations*
536 *on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021*. 2021.
537 [https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-](https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021)
538 [covid-19-vaccine-astrazeneca-17-june-2021](https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021).
- 539 12. Chandini Raina MacIntyre, et al., *Thrombosis with Thrombocytopenia Syndrome (TTS)*
540 *following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–*
541 *benefit analysis for people < 60 years in Australia*. *Vaccine*, 2021. **39**(34): p. 4784-4787.
- 542 13. Nicholas Biddle; Ben Edwards; Matthew Gray; Kate Sollis, *Vaccine willingness and concerns*
543 *in Australia: August 2020 to April 2021*. 2021, Australian National University.
544 [https://csrcm.cass.anu.edu.au/sites/default/files/docs/2021/5/Vaccine_willingness_and_concern](https://csrcm.cass.anu.edu.au/sites/default/files/docs/2021/5/Vaccine_willingness_and_concerns_in_Australia_-_August_2020_to_April_2021.pdf)
545 [s_in_Australia_-_August_2020_to_April_2021.pdf](https://csrcm.cass.anu.edu.au/sites/default/files/docs/2021/5/Vaccine_willingness_and_concerns_in_Australia_-_August_2020_to_April_2021.pdf).
- 546 14. Australian Government Department of Health *COVID-19 summary statistics*. Coronavirus
547 (COVID-19) case numbers and statistics, 2021. [https://www.health.gov.au/news/health-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics)
548 [alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics)
549 [statistics#covid19-summary-statistics](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics).
- 550 15. Australian Government Department of Health *COVID-19 vaccination – Weighing up the*
551 *potential benefits against risk of harm from COVID-19 Vaccine AstraZenec*. 2021.
552 [https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-](https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca)
553 [potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca](https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca).
- 554 16. Norman Fenton; Martin Neil, *Risk Assessment and Decision Analysis with Bayesian*
555 *Networks*. 1 ed. 2012, USA: CRC Press. 524.
- 556 17. Vincenzina Vitale;D’Urso, Pierpaolo, and De Giovanni, Livia, *Spatio-temporal Object-*
557 *Oriented Bayesian Network modelling of the COVID-19 Italian outbreak data*. *Spatial*
558 *Statistics*, 2021: p. 100529.
- 559 18. Edoardo Bertone, et al., *Effectiveness of the Early Response to COVID-19: Data Analysis and*
560 *Modelling*. *Systems*, 2020. **8**(2).
- 561 19. Junyi Wang;Zhai, Xueting, and Luo, Qiuju. *How COVID-19 Impacts Chinese Travelers’*
562 *Mobility Decision-Making Processes: A Bayesian Network Model*. in *Information and*

- 563 *Communication Technologies in Tourism 2021*. 2021. Cham: Springer International
564 Publishing.
- 565 20. Georgina Prodhan and Fenton, Norman, *Extending the range of COVID-19 risk factors in a*
566 *Bayesian network model for personalised risk assessment*. medRxiv, 2020: p.
567 2020.10.20.20215814.
568 <http://medrxiv.org/content/early/2020/10/21/2020.10.20.20215814.abstract>.
- 569 21. K. Lai and Yanushkevich, S., *Machine Reasoning to Assess Pandemics Risks: Case of USS*
570 *Theodore Roosevelt*. ArXiv, 2020. **abs/2008.11040**. <https://arxiv.org/abs/2008.11040>.
- 571 22. Norman E. Fenton, et al., *A Bayesian network model for personalised COVID19 risk*
572 *assessment and contact tracing*. medRxiv, 2021: p. 2020.07.15.20154286.
573 <http://medrxiv.org/content/early/2021/01/05/2020.07.15.20154286.abstract>.
- 574 23. Scott McLachlan, et al., *The fundamental limitations of COVID-19 contact tracing methods*
575 *and how to resolve them with a Bayesian network approach*. 2020.
576 <http://dx.doi.org/10.13140/RG.2.2.27042.66243>.
- 577 24. Yue Wu, et al., *Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian*
578 *network modelling*. *Epidemiology and Infection*, 2021. **149**: p. e166.
- 579 25. Rachel Butcher and Fenton, Norman, *Extending the range of symptoms in a Bayesian*
580 *Network for the Predictive Diagnosis of COVID-19*. medRxiv, 2020: p.
581 2020.10.22.20217554.
582 <http://medrxiv.org/content/early/2020/10/26/2020.10.22.20217554.abstract>.
- 583 26. Edward Burn, et al., *Background rates of five thrombosis with thrombocytopenia syndromes*
584 *of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and*
585 *2019 and patient profiles from 25.4 million people in six European countries*. medRxiv, 2021:
586 p. 2021.05.12.21257083.
587 <http://medrxiv.org/content/early/2021/09/17/2021.05.12.21257083.abstract>.
- 588 27. Espen Saxhaug Kristoffersen, et al., *Incidence and Mortality of Cerebral Venous Thrombosis*
589 *in a Norwegian Population*. *Stroke*, 2020. **51**(10): p. 3023-3029.

- 590 28. W. Ageno, et al., *Incidence rates and case fatality rates of portal vein thrombosis and Budd-*
591 *Chiari Syndrome*. *Thromb Haemost*, 2017. **117**(4): p. 794-800.
- 592 29. James B. Bussel; Jean M. Connors; Douglas B. Cines; Cynthia E. Dunbar; Laura C.
593 Michaelis; Lisa Baumann Kreuziger; Agnes Y.Y. Lee; Ingrid Pabinger-Fasching *Thrombosis*
594 *with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic*
595 *Thrombocytopenia)*. 2021. [https://www.hematology.org/covid-19/vaccine-induced-immune-](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia)
596 [thrombotic-thrombocytopenia](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia).
- 597 30. Maxime Taquet, et al., *Cerebral venous thrombosis and portal vein thrombosis: A*
598 *retrospective cohort study of 537,913 COVID-19 cases*. *EClinicalMedicine*, 2021. **39**: p.
599 101061.
- 600 31. NSW Government *NSW COVID-19 cases data*. 2021. [https://data.nsw.gov.au/nsw-covid-19-](https://data.nsw.gov.au/nsw-covid-19-data/cases)
601 [data/cases](https://data.nsw.gov.au/nsw-covid-19-data/cases).
- 602 32. Australian Government Department of Health *Cases and deaths by age and sex*. Coronavirus
603 (COVID-19) case numbers and statistics, 2021. [https://www.health.gov.au/news/health-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#cases-and-deaths-by-age-and-sex)
604 [alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#cases-and-deaths-by-age-and-sex)
605 [statistics#cases-and-deaths-by-age-and-sex](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#cases-and-deaths-by-age-and-sex).
- 606 33. Australian Government Department of Health *National Notifiable Diseases Surveillance*
607 *System public datasets*. 2021.
608 <https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-pub-datasets.htm>.
- 609 34. Doherty Institute, *Doherty modelling report revised 10th August 2021*. 2021, Doherty
610 Institute. p. Table S2.5.
611 [https://www.doherty.edu.au/uploads/content_doc/DohertyModelling_NationalPlan_and_Adde-](https://www.doherty.edu.au/uploads/content_doc/DohertyModelling_NationalPlan_and_Addendum_20210810.pdf)
612 [ndum_20210810.pdf](https://www.doherty.edu.au/uploads/content_doc/DohertyModelling_NationalPlan_and_Addendum_20210810.pdf).
- 613 35. Vaccine Effectiveness Expert Panel (VEEP) *VEEP: Vaccine effectiveness table, 16 July 2021*.
614 2021. [https://www.gov.uk/government/publications/veep-vaccine-effectiveness-table-16-july-](https://www.gov.uk/government/publications/veep-vaccine-effectiveness-table-16-july-2021)
615 [2021](https://www.gov.uk/government/publications/veep-vaccine-effectiveness-table-16-july-2021).

- 616 36. Australian Government Department of Health *ATAGI update following weekly COVID-19*
617 *meeting – 25 August 2021*. 2021. [https://www.health.gov.au/news/atagi-update-following-](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-25-august-2021)
618 [weekly-covid-19-meeting-25-august-2021](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-25-august-2021).
- 619 37. Australian Government Department of Health *ATAGI update following weekly COVID-19*
620 *meeting – 1 September 2021*. 2021. [https://www.health.gov.au/news/atagi-update-following-](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-1-september-2021)
621 [weekly-covid-19-meeting-1-september-2021](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-1-september-2021).
- 622 38. Australian Government Department of Health *Australian Technical Advisory Group on*
623 *Immunisation (ATAGI) weekly COVID-19 meeting on 8 September 2021 update*. 2021.
624 [https://www.health.gov.au/news/australian-technical-advisory-group-on-immunisation-atagi-](https://www.health.gov.au/news/australian-technical-advisory-group-on-immunisation-atagi-weekly-covid-19-meeting-on-8-september-2021-update)
625 [weekly-covid-19-meeting-on-8-september-2021-update](https://www.health.gov.au/news/australian-technical-advisory-group-on-immunisation-atagi-weekly-covid-19-meeting-on-8-september-2021-update).
- 626 39. Australian Government Department of Health *ATAGI update following weekly COVID-19*
627 *meeting – 15 September 2021*. 2021. [https://www.health.gov.au/news/atagi-update-following-](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-15-september-2021)
628 [weekly-covid-19-meeting-15-september-2021](https://www.health.gov.au/news/atagi-update-following-weekly-covid-19-meeting-15-september-2021).
- 629 40. Australian Bureau of Statistics *Data downloads - time series spreadsheets*. National, state and
630 territory population, 2021. [https://www.abs.gov.au/statistics/people/population/national-state-](https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020#data-download)
631 [and-territory-population/dec-2020#data-download](https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020#data-download).
- 632 41. Australian Government Department of Health *COVID-19 vaccination – Primary care*
633 *approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca*
634 *vaccine*. 2021. [https://www.health.gov.au/resources/publications/covid-19-vaccination-](https://www.health.gov.au/resources/publications/covid-19-vaccination-primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-astrazeneca-vaccine)
635 [primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-](https://www.health.gov.au/resources/publications/covid-19-vaccination-primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-astrazeneca-vaccine)
636 [astrazeneca-vaccine](https://www.health.gov.au/resources/publications/covid-19-vaccination-primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-astrazeneca-vaccine).
- 637 42. Vivien Chen; Jennifer L. Curnow; Huyen Tran; Philip Young-Ill Choi, *Australian New*
638 *Zealand approach to diagnosis and management of vaccine induced immune thrombosis and*
639 *thrombocytopenia*. Medical Journal of Australia, 2021.
- 640 43. VITT Communication Committee *THANZ Multidisciplinary VITT Guideline for Doctors*.
641 2021. <https://www.thanz.org.au/news/vitt-multidisciplinary-guideline-for-doctors>.

- 642 44. Ash K. Clift, et al., *Living risk prediction algorithm (QCOVID) for risk of hospital admission*
643 *and mortality from coronavirus 19 in adults: national derivation and validation cohort study.*
644 *BMJ*, 2020. **371**: p. m3731.
- 645 45. Johns Hopkins. *COVID-19 Risk Tools*. COVID-19 Risk Tools 2021 [cited 25 September
646 2021]; Available from: <https://covid19risktools.com:8443/riskcalculator#mainbody>.
- 647 46. Viet-Thi Tran, et al., *Impact of an interactive web tool on patients' intention to receive*
648 *COVID-19 vaccination: a before-and-after impact study among patients with chronic*
649 *conditions in France.* *BMC Medical Informatics and Decision Making*, 2021. **21**(1): p. 228.
- 650 47. ISARIC4C (Coronavirus Clinical Characterisation Consortium). *ISARIC4C Mortality Score.*
651 *ISARIC4C* 2021; Available from: <https://isaric4c.net>.
- 652 48. National Institute on Ageing. *My COVID-19 Visit Risk Calculator.* 2021 [cited 25 September
653 2021]; Available from: <https://covidvisitrisk.com/riskscore-english.html>.
- 654 49. The microCOVID Project. *microCOVID Project.* 2021 [cited 25 September 2021]; Available
655 from: <https://www.microcovid.org/about>.
- 656 50. Lifespan; Warren Alpert Medical School of Brown University. *MyCOVIDRisk.* 2021 [cited
657 25 September 2021]; Available from: <https://mycovidrisk.app>.

**Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using
an adaptable Bayesian network modelling framework**

Table 1. Summary of data sources, assumptions, and prior distributions for a Bayesian network to assess risks versus benefits of the AstraZeneca COVID-19 vaccine.

Model inputs	Data sources, assumptions, rationale	Reference
Age distribution of infections from delta variant	NSW COVID-19 case data from 1/6/2021 to 13/8/2021 were used to provide estimates of age distribution of infections from delta variant. Case data published daily by NSW Health, for the following age categories: 0-19, 5-year age groups from 20-69 years, and 70+. For cases in the 0-19 age group, assumed that 40% were aged 0-9, and 60% aged 10-19 (based on age distribution of cases reported by NNDSS). Date range used was selected to reflect the first 6 weeks of delta outbreak, when vaccination coverage was relatively low. No significant change in age distribution of cases to 29/8/2021. See Appendix A, Table A1.	31,32
Age distribution of infections from alpha/wild variants	COVID-19 cases reported in Australia from January to December 2020 were used to provide estimates of age distribution from alpha/wild variants. Data sourced from National Notifiable Diseases Surveillance System. See Appendix A, Table A2.	14,33
Case fatality rates of COVID-19 cases	COVID-19 cases reported in Australia from January 2020 to 13/8/2021 were used to provide estimates of age-specific case fatality. Data sourced from National Notifiable Diseases Surveillance System. See Appendix A, Table A3.	14,33
Community transmission levels	<p>Chance of infection over 6 months calculated for different levels of community transmission. See Appendix A, Table A4.</p> <p>Definitions of low, medium, and high transmission as defined by ATAGI document ‘Weighing up the potential benefits and risk of harm from COVID-19 Vaccine AstraZeneca’. Low – similar to first wave in Australia (equivalent to 0.05% of population infected over 6 months). Medium – similar to second wave in VIC in 2020 (equivalent to 0.045% of population infected over 6 months). High – similar to Europe in January 2021 (equivalent to 5.76% of population infected over 6 months).</p> <p>Also included transmission scenarios equivalent to: zero transmission; 1% and 2% chance of infection over 6 months; 200 cases/day and 1000 cases/day in NSW; 1000 cases/day in VIC; 1000 cases/day in QLD. Other transmission levels can be added to model.</p>	15
Chance of infection by age group	Chance of infection differed between age groups and by variants. Calculated chance of infection by age group if overall community transmission of 1%. Calculations based on age distribution of infections from delta and alpha/wild variants, and age distribution of Australian population. See Appendix A, Table A5.	
Vaccine effectiveness against symptomatic infection	<p>Delta variant (ATAGI recommended data used in Doherty transmission model):</p> <ul style="list-style-type: none"> • 33% effective after 1st dose • 61% effective after 2nd dose <p>(Note: Public Health England estimates effectiveness of 45% after 1st dose, and 70% after 2nd dose)</p>	34,35

	<p>Alpha variant (from Vaccine effectiveness Expert Panel, Public Health England):</p> <ul style="list-style-type: none"> • 60% effective after 1st dose • 80% effective after 2nd dose 	
Vaccine effectiveness against death	<p>Delta variant (ATAGI recommended data used in Doherty transmission model):</p> <ul style="list-style-type: none"> • 69% effective after 1st dose • 90% effective after 2nd dose <p>(Note: Public Health England estimates effectiveness of 80% after 1st dose, and 95% after 2nd dose).</p> <p>Alpha variant (from Vaccine effectiveness Expert Panel, Public Health England):</p> <ul style="list-style-type: none"> • 80% effective after 1st dose • 95% effective after 2nd dose 	34,35
Thrombosis and Thrombocytopenia Syndrome (TTS) after AZ vaccine	<p>Model uses data reported by ATAGI update following weekly COVID-19 meeting on 25/8/2021.</p> <p>Estimated rate per 100,000 1st dose of AZ vaccinations:</p> <ul style="list-style-type: none"> • Age <50: 2.5 • Age 50-59: 2.7 • Age 60-69: 1.6 • Age 70-79: 2.1 • Age ≥80: 1.6 • For age ≥70 in model, used rate of 1.85 (average of rates for 70-79 and ≥80). <p>Estimated rate per 100,000 after 2nd dose of AZ vaccinations: 0.18 per 100,000 (no age specific rates available).</p> <p>Case fatality rate in Australia ~5% (noting that higher rates reported in UK ~18%).</p> <p>For sensitivity analysis, data from ATAGI reports on 1/9/2021, 8/9/2021, and 15/9/2021 were used.</p>	36–39
Background rates of atypical venous thrombotic disorders	<p>Background rates (in population not infected with and not vaccinated for COVID-19) of atypical venous thrombotic disorder (CVST and PVT) over 6 weeks were calculated for each age group to provide a comparison with chance of TTS after AZ vaccine.</p> <p>CVST data from Kristoffersen <i>et al.</i></p> <ul style="list-style-type: none"> • Age-specific rates per million population per year: <ul style="list-style-type: none"> ○ Age <20: 10.8 ○ Age 20-49: 18.0 ○ Age 50-69: 21.1 ○ Age ≥70: 20.7 • Case fatality of 7% for all age groups. • Assumed equal rates in males and females. 	27,28

	<p>PVT data from Ageno <i>et al.</i></p> <ul style="list-style-type: none"> • Age-specific rates per million population per year: <ul style="list-style-type: none"> ○ Age <20: 0 ○ Age 20-29: 5.5 ○ Age 30-39: 7.25 ○ Age 40-49: 15.75 ○ Age 50-59: 25.5 ○ Age 60-69: 49.5 ○ Age ≥70: 55.125 • Case fatality of 27.2% for all age groups. • Assumed equal rates in males and females. 	
Atypical venous thrombotic disorders associated with COVID-19 infection	<p>Rates of CVST and PVT in COVID-19 cases from a retrospective cohort study using data primarily from the USA.</p> <p>CVT:</p> <ul style="list-style-type: none"> • Cases per million COVID-19 infections: <ul style="list-style-type: none"> ○ Male: 28.87 ○ Female: 54.20 • Case fatality 17.4% for both sexes. • Assumed same rates for all age groups. <p>PVT:</p> <ul style="list-style-type: none"> • Cases per million COVID-19 infections: <ul style="list-style-type: none"> ○ Male: 483 ○ Female: 318 • Case fatality 19.9% for both sexes. • Assumed same rates for all age groups. 	30
Prior distributions*	Assumptions	Reference
Age distribution of Australian population	Australian Bureau of Statistics. National population estimates, December 2020. See Appendix A, Table A6.	40
Gender distribution of Australian population	50% male, 50% female	
Variants	90% delta, 10% alpha/wild	
Vaccine coverage	70% received 1 st dose, 35% received 2 nd dose	

ATAGI=Australian Technical Advisory Group on Immunisation; CVST=Cerebral venous sinus thrombosis; PVT=Portal vein thrombosis. *Note that prior distributions do not affect results of scenario analysis but enables the model to provide population-level estimates. Assumptions can be changed as the situation evolves.

Table 2. Summary of nodes and relationships between nodes in a Bayesian network for assessing risks versus benefits of the AstraZeneca COVID-19 vaccine.

Node name (number)	Description	Potential values	Node type	Parent nodes	Child nodes
AZ vaccine doses (n1)	Version 1: Vaccine dose number Version 2: Vaccine coverage in population	Version 1: None, 1 st dose, 2 nd dose Version 2: None, one dose only, two doses	Input	N/A – Default priors: 30% unvaccinated, 35% had one dose only, 35% had two doses.	n6, n10, n9
Age group (n2)	Age group	0-9,10-19, 20-29,30-39, 40-49, 50-59, 60-69, 70+	Input	N/A – Default priors: population distribution of Australia	n6, n7, n8, n11, n18
SARS CoV-2 variant (n3)	Dominant SARS CoV-2 variant(s) currently circulating	Alpha/wild, Delta	Input	N/A – Default priors: 5% Alpha/wild and 95% Delta	n9, n10, n11
Intensity of community transmission - x% over 6 months (n4)	Probability of infection over 6-months based on different levels of community transmission	None, ATAGI definitions of low, med, high, 1%, 2%, NSW 200 cases/day, NSW 1000 cases/day, Vic 1000 cases/day, QLD 1000 cases/day	Input	N/A – Defaults to uniform distribution	n14
Sex (n5)	Sex	Male, female	Input	N/A – Defaults to uniform distribution	n12, n13, n18
Vaccine-associated TTS (n6)	Probability of AZ vaccine-associated TTS	Yes, no	Intermediate	AZ vaccine doses (n1), Age group (n2)	n15
CVST over 6 weeks (n7)	Probability of developing CVST over 6 weeks	Yes, no	Intermediate	Age group (n2)	n16
PVT over 6 weeks (n8)	Probability of developing PVT over 6 weeks	Yes, no	Intermediate	Age group (n2)	n17
Vaccine effectiveness against symptomatic infection (n9)	Effectiveness of the vaccine at preventing symptomatic SARS CoV-2 infection	Yes, no	Intermediate	AZ vaccine doses (n1), SARS CoV-2 variant (n3)	n14
Vaccine effectiveness against death (n10)	Effectiveness of the vaccine at preventing deaths from symptomatic SARS CoV-2 infection	Yes, no	Intermediate	AZ vaccine doses (n1), SARS CoV-2 variant (n3)	n18
Relative risk of infection depending on age and variant (n11)	Relative risk of COVID-19 infection depending on age and variant	Yes, no	Intermediate	Age group (n2), SARS CoV-2 variant (n3)	n14
CVST from Covid infection (n12)	Probability of developing CVST if develops symptomatic COVID-19	Yes, no	Intermediate	Sex (n5), Risk of symptomatic infection under current transmission and vaccination status (n12)	n20

PVT from Covid infection (n13)	Probability of developing PVT if develops symptomatic COVID-19	Yes, no	Intermediate	Sex (n5), Risk of symptomatic infection under current transmission and vaccination status (n12)	N/A
Risk of symptomatic infection under current transmission and vaccination status (n14)	Probability of symptomatic COVID-19	Yes, no	Intermediate	Intensity of community transmission - x% over 6 months (n4), Vaccine effectiveness against symptomatic infection (n9), Relative risk of infection depending on age and variant (n11)	n19
Die from vaccine-associated TTS (n15)	Proportion of the population that will die from vaccine-associated TTS	Yes, no	Outcome	Vaccine-associated TTS (n6)	N/A
Die from CVST (n16)	Probability of dying from CVST (background rate in those who have not had vaccine or infection)	Yes, no	Outcome	CVST over 6 weeks (n7)	N/A
Die from PVT (n17)	Probability of dying from PVT (background rate in those who have not had vaccine or infection)	Yes, no	Outcome	PVT over 6 weeks (n8)	N/A
Die from Covid (n18)	Probability of dying from COVID-19	Yes, no	Outcome	Age (n2), Sex (n5), Vaccine effectiveness against death (n10), Risk of symptomatic infection under current transmission and vaccination status (n12)	N/A
Die from Covid-related CVST (n19)	Probability of dying from COVID-19 related CVST	Yes, no	Outcome	CVST from SARS COV-2 infection (n13)	N/A
Die from Covid-related PVT (n20)	Probability of dying from COVID-19 related PVT	Yes, no	Outcome	PVT from SARS COV-2 infection (n14)	N/A

Table 3. Evolving evidence on incidence and case-fatality rate (CFR) of vaccine-associated Thrombosis with Thrombocytopenia Syndrome (TTS) in Australia in August-September 2021, and influence on estimated TTS-related deaths by age group.

Age group (years)	Estimated incidence of TTS per million 1 st doses of AZ vaccinations ^a				Cases ^b , deaths ^b , and CFR ^c from 1 st doses of AZ vaccinations				Estimated deaths per million 1 st doses of AZ vaccinations based on observed CFR to date				Difference in estimated deaths per million compared to 25/8/2021		
	25/8/2021	1/9/2021	8/9/2021	15/9/21	25/8/2021	1/9/2021	8/9/2021	15/9/21	25/8/2021	1/9/2021	8/9/2021	15/9/21	1/9/2021	8/9/2021	15/9/2021
<50	25	22	20	18	Cases=115	Cases=125	Cases=132	Cases=134	1.30	1.41	1.22	1.08	0.11	-0.08	-0.22
50-59	27	26	29	28	Deaths=6	Deaths=8	Deaths=8	Deaths=8	1.40	1.66	1.77	1.68	0.26	0.37	0.28
60-69	16	17	16	16	CFR=5.2%	CFR=6.4%	CFR=6.1%	CFR=6.0%	0.83	1.09	0.98	0.96	0.26	0.14	0.13
70-79	21	21	20	20	(95% CI 1.9-11.0%)	(95% CI 2.8-12.2%)	(95% CI 2.7-11.6%)	(95% CI 2.6-11.4%)	1.09	1.34	1.22	1.20	0.25	0.13	0.11
≥80	16	16	17	19					0.83	1.02	1.04	1.14	0.19	0.21	0.31

^a Incidence of TTS in Australia reported by ATAGI.

^b Cumulative cases and deaths to date in Australia, all ages.

^c CFR=Case fatality rate for all ages combined, and binomial exact 95% confidence interval.

Table 4. Impact of theoretical reduction in vaccine effectiveness against delta variant on estimated deaths, assuming 70% of population had first dose, and 35% had two doses.

Delta variant	Current model assumptions	If 5% less effective	If 10% less effective
Vaccine effectiveness against symptomatic infection after	33%	28%	23%
• 1 st dose	61%	56%	51%
• 2 nd dose			
Vaccine effectiveness against death after			
• 1 st dose	69%	64%	59%
• 2 nd dose	90%	85%	80%
% Increase in estimated deaths compared to current model assumptions of vaccine effectiveness	N/A	7.1%	15.1%




Figure 1. Example Bayesian network showing three nodes (white boxes), links (arrows), and conditional probability table (CPT) for *Die from Covid* node (blue table). Data in figure are fictitious and for illustrative purposes only. The model assumes 90% vaccine effectiveness against death and even distribution of males or females in the population; these numbers are entered as priors because the nodes do not have parents. The model assumes case fatality rate of 20% in males and 10% in females. The CPT for *Die from Covid* shows that if the vaccine is effective, probability of dying is 0% for both genders. If the vaccine is not effective, the probability of dying is 20% for males and 10% and females. Fig 1a) shows the BN in its default state; if the vaccine was 90% effective, we expect an overall 1.5% chance of dying from COVID (e.g., in a population of 1000 people, the vaccine was not effective in 100 people. Of these 100 people, we estimate 10 deaths out of 50 males, and 5 deaths out of 50 females, i.e., total of 15 deaths out of 1000 people, or 1.5%). Fig 1b) shows an example scenario analysis of ‘what is the chance of a male dying if the vaccine was not effective?’ Selected states in each node are underlined, and the model updates the chance of dying from COVID to 20% under this scenario.




Figure 2. Bayesian network for assessing risks versus benefits of the AstraZeneca COVID-19 vaccine.




Figure 3. Estimated COVID-19 deaths prevented over 6 months per million population of each age group if 70% had first dose, and 35% had two doses of AZ vaccine under a) low, b) medium, and c) high levels of community transmission; and d) estimated deaths from AZ vaccine-associated TTS if 70% of the population had first dose, and 35% had two doses. (Note the large variations in scale in y-axes between each graph).




Figure 4. Number of times more likely to develop and die from atypical blood clots (CVST and PVT) from COVID-19 infection than AZ vaccine-associated TTS, by age group and sex.




Figure 5. Change in age-sex specific case fatality rate for COVID-19 if one or five extra deaths in each subgroup: a) CFR in males, b) CFR in females, c) absolute difference in CFR if one or five extra deaths. (Based on COVID-19 cases and deaths in Australia by 31/8/2021).